Phase 2 N=32 Montelukast Therapy on Alzheimer's Disease
Alzheimer Disease
Primary: Number of Participants With Any Gastrointestinal (GI) Symptoms — 1; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=57 A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia
Achondroplasia
Primary: Annualized Height Velocity (cm/Year) After 52 Weeks of Double-blind Treatment — 4.09; 4.52; 5.16; 5.42 cm/year — p== 0.6004
Phase 2 N=8 Study of DS-5141b in Patients With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Primary: Number of Participants Reporting at Least One Treatment-emergent Adverse Event (TEAE) In Participants With Duchenne Muscular Dystrophy — 3; 5 Participants
Phase 2 N=155 A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia
Parkinson Disease
Primary: Change in Average Daily Hours of ON-time Without Troublesome Dyskinesia With Mesdopetam Compared to Placebo as Assessed With 24-hour Patient Home Diaries From Baseline…
Phase 2 N=106 BMS-986012 in Relapsed/Refractory SCLC
Small Cell Lung Cancer
Primary: Number of Participants With Adverse Events (AEs) — 7; 6; 29; 35 Participants
Phase 2 N=256 Aggressive Antipyretics for Fever Reduction in CNS Malaria
Malaria · Seizures · Coma
Primary: Mean Maximum Temperature — 38.6; 39.2 degrees of Celsius — p=<0.0001
Phase 2 N=54 Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant
Hepatocellular Carcinoma · HCC
Primary: Freedom From Progression Over Time — 0; 3.4; 0; 26.5 percentage of patients with progression
Phase 2 N=43 A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Carcinoid Tumors
Primary: Progression-Free Survival (PFS) — 14.2 months
Phase 2 N=61 JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
Primary Myelofibrosis · Secondary Myelofibrosis
Primary: 2-year Overall Survival (OS) in Patients With Myelofibrosis (MF) Who Receive Treatment With a JAK Inhibitor Followed by an Allogeneic Transplant — 78.24 percentage of…
Phase 2 N=5 Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer
Pancreatic Cancer Non-resectable
Primary: Grade 3 or Higher Adverse Event(s) as a Measure of Safety and Tolerability — 3 Participants
Phase 2 N=24 A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection
Hepatitis B
Primary: Panel 1 and 2: Absolute Change From Baseline in the Percentage of Hepatitis B Surface Antigen (HBsAg) Hepatocytes at Week 40 — -78.46; -5.68 percentage of HBsAg…
Phase 2 N=158 LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
Melanoma
Primary: Overall Response Rate (ORR): Part II — 2.6; 0; 0; 0 Percentage of participants
Phase 2 N=188 A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia
Hypercholesterolemia
Primary: Percent Change in LDL-C From Baseline to Week 12 — -10.59; -21.85; -21.26; -1.92 Percent Change — p=<0.001
Phase 2 N=46 Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Primary: 4-Cycle Induction Overall Response Rate (ORR) — 95 percentage of participants
Phase 2 N=45 Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Urinary Toxicity Assessed by CTCAE v4.0 — 33 Participants